SPOTLIGHT -
Associate Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT.
Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.
Belantamab mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
Belantamab mafodotin-blmf is now indicated for adult patients with relapsed or refractory myeloma who have received at least 4 prior therapies.
Remdesivir in the Treatment of COVID-19
On October 22, 2020, the FDA approved remdesivir (Veklury; Gilead) as the first treatment for coronavirus disease 2019 (COVID-19).
Azacitidine Tablets for Acute Myeloid Leukemia
The FDA approved azacitidine tablets (Onureg; Celgene Corporation) on September 1, 2020
Selpercatinib for NSCLC and Thyroid Cancer With RET Mutations or Fusions
On May 8, 2020, the FDA granted accelerated approval to selpercatinib (Retevmo; Eli Lilly and Company).
New Drug Review: Erdafitinib
First oral drug for advanced or metastatic bladder cancer.
New Drug Review: Spravato
Both responder and remitter patients experienced a statistically significant longer time to relapse with esketamine compared to the placebo
Apalutimide for Prostate Cancer: What to Know
FDA approves apalutamide for castration-resistant prostate cancer.
FDA Approves Emicizumab-kxwh for Hemophilia A
Emicizumab-kxwh brings together factors IXa and X to restore the function of the missing activated factor VIII and the blood clotting process.
Tisagenlecleucel (Kymriah) for Acute Lymphoblastic Leukemia
A new era of treatment has arrived-here’s what you need to know.
FDA Approves Rucaparib for Advanced Ovarian Cancer
The New Drug Review for April
